BR112014021240A2 - uso de igg policlonal - Google Patents

uso de igg policlonal

Info

Publication number
BR112014021240A2
BR112014021240A2 BR112014021240A BR112014021240A BR112014021240A2 BR 112014021240 A2 BR112014021240 A2 BR 112014021240A2 BR 112014021240 A BR112014021240 A BR 112014021240A BR 112014021240 A BR112014021240 A BR 112014021240A BR 112014021240 A2 BR112014021240 A2 BR 112014021240A2
Authority
BR
Brazil
Prior art keywords
polyclonal igg
igg use
polyclonal
igg
Prior art date
Application number
BR112014021240A
Other languages
English (en)
Portuguese (pt)
Inventor
Maria Reipert Birgit
Hermann Corinna
Hartung Hans-Peter
Schwarz Hans-Peter
Ehrlich Hartmut
Tzekova Nevena
Kuery Patrick
Bunk Sebastian
Original Assignee
Baxter Healthcare Sa
Baxter Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Healthcare Sa, Baxter Int filed Critical Baxter Healthcare Sa
Publication of BR112014021240A2 publication Critical patent/BR112014021240A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39516—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
BR112014021240A 2012-02-29 2013-02-28 uso de igg policlonal BR112014021240A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261605117P 2012-02-29 2012-02-29
PCT/US2013/028350 WO2013130826A2 (en) 2012-02-29 2013-02-28 Igg stimulated remyelination of peripheral nerves

Publications (1)

Publication Number Publication Date
BR112014021240A2 true BR112014021240A2 (pt) 2018-09-18

Family

ID=47884569

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014021240A BR112014021240A2 (pt) 2012-02-29 2013-02-28 uso de igg policlonal

Country Status (21)

Country Link
US (5) US8986670B2 (cg-RX-API-DMAC7.html)
EP (2) EP3590960B1 (cg-RX-API-DMAC7.html)
JP (3) JP6335800B2 (cg-RX-API-DMAC7.html)
KR (3) KR102673154B1 (cg-RX-API-DMAC7.html)
CN (4) CN104302666A (cg-RX-API-DMAC7.html)
AR (2) AR090211A1 (cg-RX-API-DMAC7.html)
AU (3) AU2013203088B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014021240A2 (cg-RX-API-DMAC7.html)
DK (2) DK2820042T3 (cg-RX-API-DMAC7.html)
EA (2) EA032000B1 (cg-RX-API-DMAC7.html)
ES (2) ES2943585T3 (cg-RX-API-DMAC7.html)
FI (1) FI3590960T3 (cg-RX-API-DMAC7.html)
HK (1) HK1248534A1 (cg-RX-API-DMAC7.html)
IL (3) IL277103B2 (cg-RX-API-DMAC7.html)
MX (2) MX369444B (cg-RX-API-DMAC7.html)
NZ (1) NZ629867A (cg-RX-API-DMAC7.html)
PL (2) PL2820042T3 (cg-RX-API-DMAC7.html)
PT (2) PT2820042T (cg-RX-API-DMAC7.html)
SG (1) SG11201405302WA (cg-RX-API-DMAC7.html)
TW (3) TWI700297B (cg-RX-API-DMAC7.html)
WO (1) WO2013130826A2 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3590960T3 (fi) * 2012-02-29 2023-04-25 Takeda Pharmaceuticals Co Perifeeristen hermojen IgG-stimuloitu remyelinaatio
US9690975B2 (en) * 2015-05-28 2017-06-27 Axogen Corporation Quantitative structural assay of a nerve graft
US11511136B2 (en) 2017-11-17 2022-11-29 The Research Foundation For The State University Of New York Method for treating damaged peripheral nerves using x-ray microbeam irradiation
EP3908256A4 (en) * 2019-01-07 2022-09-21 Mallinckrodt Ard IP Unlimited Company METHOD TO PROMOTE REMYELINATION
GB201907882D0 (en) 2019-06-03 2019-07-17 Cyprus Foundation For Muscular Dystrophy Res Methods
EP4737584A1 (en) * 2023-06-30 2026-05-06 FUJIFILM Corporation Method for evaluating intercellular interaction of neuroinflammation

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE348942B (cg-RX-API-DMAC7.html) 1970-06-02 1972-09-18 Statens Bakteriologiska Labor
AT376367B (de) 1983-03-16 1984-11-12 Immuno Ag Verfahren zur herstellung von therapeutisch verabreichbaren, in endbehaeltern abgefuellten plasmaderivaten
DK166763B1 (da) 1983-03-16 1993-07-12 Immuno Ag Immunoglobulin-g-holdig fraktion
ATE36457T1 (de) 1983-05-02 1988-09-15 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen krankheitserregern.
AT389815B (de) 1984-03-09 1990-02-12 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern in blutprodukten
AT390560B (de) 1986-05-30 1990-05-25 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern
JP2871709B2 (ja) 1988-11-21 1999-03-17 住友製薬株式会社 免疫グロブリンg結合活性を有する新規な蛋白質プロテインh、該蛋白質をコードする遺伝子及び該蛋白質の製造法
US5177194A (en) 1990-02-01 1993-01-05 Baxter International, Inc. Process for purifying immune serum globulins
WO1992003536A1 (en) * 1990-08-15 1992-03-05 University Of Miami And Its School Of Medicine Autotransplantation of schwann cells to promote nervous system repair
AT402891B (de) 1991-06-20 1997-09-25 Immuno Ag Verfahren zur herstellung eines inaktivierten blutproduktes
EP0674531A1 (de) 1992-12-16 1995-10-04 IMMUNO Aktiengesellschaft Verfahren zur herstellung eines virussicheren biologischen präparates
FR2706466B1 (fr) 1993-06-14 1995-08-25 Aetsrn Concentré d'immunoglobulines G à usage thérapeutique et procédé de production dudit concentré.
HRP940645A2 (en) 1993-10-06 1996-12-31 Immuno Ag Process for virus deactivation in the presence of polyalkylene glycol and the pharmaceutical preparation thus obtained
TW491855B (en) 1996-08-07 2002-06-21 Csl Ltd Purification of immunoglobulins
US5886154A (en) 1997-06-20 1999-03-23 Lebing; Wytold R. Chromatographic method for high yield purification and viral inactivation of antibodies
ID27417A (id) 1998-06-09 2001-04-05 Statens Seruminstitut Proses untuk memproduksi immunoglobulin untuk pemberian melalui intravena dan produk-produk immunoglobulin lainnya
SE0001128D0 (sv) 2000-03-30 2000-03-30 Amersham Pharm Biotech Ab A method of producing IgG
EP2287190B1 (en) * 2000-05-10 2014-12-17 Mayo Foundation For Medical Education And Research Human igm antibodies with the capability of inducing remyelination, and diagnostic and therapeutic uses thereof particularly in the central nervous system
FR2824568B1 (fr) 2001-05-11 2004-04-09 Lab Francais Du Fractionnement Procede de preparation de concentres d'immunoglobulines humaines a usage therapeutique
JP2003070465A (ja) * 2001-08-31 2003-03-11 Keio Gijuku シュワン細胞の培養方法
JP2007521249A (ja) 2003-01-24 2007-08-02 エラン ファーマシューティカルズ,インコーポレイテッド 脱髄疾患および麻痺のための組成物ならびに再有髄化剤を投与することによるそれらの治療
US20070244305A1 (en) 2004-01-30 2007-10-18 Suomen Punainen Risti Veripalvelu Process for The Manufacture of Virus Safe Immunoglobulin
CA2557229C (en) 2004-02-27 2012-07-10 Octapharma Ag A method of providing a purified, virus safe antibody preparation
EA017403B1 (ru) * 2007-02-02 2012-12-28 Байоджен Айдек Эмэй Инк. Использование семафорина 6а в качестве промотора миелинизации и дифференцировки олигодендроцитов
US7854703B2 (en) 2007-09-25 2010-12-21 Intel Corporation Peripheral neuropathy detection
CA2643496C (en) 2008-11-06 2015-02-03 Michael Fehlings The therapeutic use of igg as a neuroprotective agent
CN102021140B (zh) * 2009-09-18 2013-04-24 上海市第一人民医院 一种分离、纯化许旺细胞的方法
FI3590960T3 (fi) * 2012-02-29 2023-04-25 Takeda Pharmaceuticals Co Perifeeristen hermojen IgG-stimuloitu remyelinaatio

Also Published As

Publication number Publication date
TWI700297B (zh) 2020-08-01
JP6335800B2 (ja) 2018-05-30
KR20140134690A (ko) 2014-11-24
AU2016201137A1 (en) 2016-03-10
CN107551269A (zh) 2018-01-09
AU2013203088B2 (en) 2015-12-03
ES2755056T3 (es) 2020-04-21
SG11201405302WA (en) 2014-09-26
US20150232536A1 (en) 2015-08-20
MX369444B (es) 2019-11-08
DK3590960T3 (da) 2023-04-24
AR090211A1 (es) 2014-10-29
EA032000B1 (ru) 2019-03-29
US20180291087A1 (en) 2018-10-11
PT2820042T (pt) 2019-10-31
IL274512A (en) 2020-06-30
AU2018200026B2 (en) 2019-12-05
EP3590960B1 (en) 2023-03-29
JP6979990B2 (ja) 2021-12-15
AU2018200026A1 (en) 2018-01-25
IL277103B1 (en) 2025-03-01
JP2015508824A (ja) 2015-03-23
FI3590960T3 (fi) 2023-04-25
MX2019012496A (es) 2020-01-20
IL274512B2 (en) 2024-07-01
JP2020059705A (ja) 2020-04-16
WO2013130826A2 (en) 2013-09-06
CN110343171A (zh) 2019-10-18
IL234303B (en) 2020-09-30
PL2820042T3 (pl) 2020-03-31
US20200216518A1 (en) 2020-07-09
WO2013130826A3 (en) 2013-12-05
KR102673154B1 (ko) 2024-06-05
US20210300997A1 (en) 2021-09-30
PL3590960T3 (pl) 2023-07-17
AR117207A2 (es) 2021-07-21
EA201892521A1 (ru) 2019-07-31
EP2820042B1 (en) 2019-07-24
KR102170615B1 (ko) 2020-10-28
AU2013203088A1 (en) 2013-09-19
KR20220045087A (ko) 2022-04-12
KR20200126005A (ko) 2020-11-05
JP6637934B2 (ja) 2020-01-29
DK2820042T3 (da) 2019-10-28
AU2016201137B2 (en) 2017-10-12
US9834593B2 (en) 2017-12-05
TW201400502A (zh) 2014-01-01
TW201838654A (zh) 2018-11-01
NZ629867A (en) 2016-09-30
MX2014010387A (es) 2015-09-25
EP2820042A2 (en) 2015-01-07
IL274512B1 (en) 2024-03-01
JP2018030856A (ja) 2018-03-01
TWI632158B (zh) 2018-08-11
US10494418B2 (en) 2019-12-03
IL277103B2 (en) 2025-07-01
EA201400966A1 (ru) 2014-12-30
US8986670B2 (en) 2015-03-24
IL277103A (en) 2020-10-29
HK1206035A1 (en) 2015-12-31
TW201736398A (zh) 2017-10-16
CN109966488A (zh) 2019-07-05
EP3590960A1 (en) 2020-01-08
US20130224150A1 (en) 2013-08-29
CN104302666A (zh) 2015-01-21
PT3590960T (pt) 2023-04-18
HK1248534A1 (zh) 2018-10-19
ES2943585T3 (es) 2023-06-14

Similar Documents

Publication Publication Date Title
CY2024011I2 (el) Αντισωματα anti-fcrn
PT2858671T (pt) Formulação de anticorpos
PT3088419T (pt) Conjugado de anticorpo anti-trop2-fármaco
DK2890397T3 (da) Antiprolactinreceptor-antistofformulering
DK2934584T3 (da) Anti-gdf15-antistoffer
HRP20181646T1 (hr) Konjugati pirolobenzodiazepin - anti-psma protutijela
BR112014024769A2 (pt) anticorpo humanizado tau
DK3049441T3 (da) Anti-PDL1-antistofformuleringer
DK3736291T5 (da) Anti-FCRH5-antistoffer
DK3117837T3 (da) Antistofformuleringer
DK3071595T3 (da) Humaniseret anti-kallikrein-2-antistof
EP3427721C0 (en) HIGH CONCENTRATION MONOCLONAL ANTIBODY FORMULATIONS
ME03675B (me) Humanizovana ili himerna anтi-cd3 antiтela
DK3708583T3 (da) Ikke-fucosylerede anti-fgfr2iiib-antistoffer
BR112014025037A2 (pt) anticorpo ou um fragmento funcional do mesmo, nucleotídeo, vetor recombinante, célula, métodos para a produção de um anticorpo ou fragmento funcional, para detecção ou ensaio de fgfr2 humano iiib, para a identificação de um indivíduo receptor de uma composição farmacêutica, e, para identificar e para produzir uma substância, forma modificada, composição, e, reagente
PL3088421T3 (pl) Przeciwciała monoklonalne do zastosowania w diagnostyce i leczeniu nowotworów i choroby autoimmunologicznej
DK3068800T3 (da) FcRn-specifikke antistoffer
DK2934582T3 (da) Anti-her2-antistofformulering
DK3431504T3 (da) Antiphospholipase d4-antistof
DK3521315T3 (da) Anti-transglutaminase-2-antistoffer
DK2828292T3 (da) Jcv-neutraliserende antistoffer
DK2935330T3 (da) Anti-notch3-antistoffer
EP2920370A4 (en) POST
DK3065774T3 (da) Anti-CCL17-antistoffer
PL3066124T4 (pl) Neuregulina-allosteryczne przeciwciała przeciwko ludzkiemu her3

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: BAXALTA GMBH (CH) ; BAXALTA INCORPORATED (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25A Requested transfer of rights approved

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP)

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]